Dr. Jing Lin is VP of Regor Therapeutics Inc., Shanghai, China. Prior to Regor, she has worked in AbbVie, Pfizer, and Sunovion/Sumitomo in the disciplines of preclinical development and clinical pharmacology over 20 years. Her extensive experience includes drug metabolism, PKPD and PBPK modelling to bridge DMPK and Toxicology results into clinical study design. Dr. Lin also has an extensive experience in regulatory filing from IND to NDA. Dr. Lin received her PhD in organic chemistry from Loyola University of Chicago and conducted a postdoctoral training in University of Washington in the field of drug metabolism.